{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:29:54Z","timestamp":1792740594190,"version":"4.5.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg\/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (\u03b2 mg\/kg). In vitro and animal studies have reported increased activity with increased daptomycin doses. There are limited clinical data on use of daptomycin at doses greater than 6 mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of higher doses (\u22658 mg\/kg) of daptomycin when administered for a variety of gram-positive infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were collected retrospectively as part of an ongoing registry (the Cubicin Outcomes Registry and Experience database) for the 2005\u20132007 program years. For the purpose of this study, the safety and efficacy of daptomycin were evaluated in patients who received doses of 8 m\/kg or higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety-four (2.6%) of 3617 patients received daptomycin doses of 6 mg\/kg or higher; 18 (19%) of those patients received doses of 10 mg\/kg or higher. The most common infections were bacteremia (30\/94), skin and skin-structure infections (22\/94), and endocarditis (15\/94). The most common pathogens were Enterococcus spp. (37\/94; 57% vancomycin-resistant) and S. aureus (28\/94; 68% methicllin-resistant). Fifty-one percent of the patients were male. 39% were aged 66 years or older, 27% had an initial creatinine clearance less than 30 mL\/min, and 17% were on dialysis. The median duration of daptomycin therapy was 15 days (minimum 1, maximum 90). Six (6.4%) of the 94 patients experienced 1 or more adverse events or abnormal laboratory value changes possibly related to daptomycin; in 2 (2.1%) of the 94 patients, daptomycin was discontinued due to treatment-related adverse events. Seventy-four (79%) patients were considered evaluable for efficacy. The overall clinical success rate was 89% (bacteremia, 91 %; skm and skin-structure infections. 88%: endocarditis. 67%)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Daptomycin was well tolerated and effective at doses of 8 mg\/kg or higher in patients with gram-positive infections. Further prospective and comparative studies of daptomycin at doses greater than 6 mg\/kg are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m085","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T23:44:38Z","timestamp":1247010278000},"page":"1211-1219","source":"Crossref","is-referenced-by-count":117,"title":["Safety and Clinical Outcomes when Utilizing High-Dose (\u22658 mg\/kg) Daptomycin Therapy"],"prefix":"10.1177","volume":"43","author":[{"given":"Pamela A","family":"Moise","sequence":"first","affiliation":[{"name":"Cubist Pharmaceuticals Inc., Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Hershberger","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I","family":"Amodio-Groton","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C","family":"Lamp","sequence":"additional","affiliation":[{"name":"Cubist Pharmaceuticals Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,7,7]]},"reference":[{"key":"bibr1-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00543-6"},{"key":"bibr2-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"bibr3-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/520192"},{"key":"bibr4-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181647037"},{"key":"bibr5-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/533592"},{"key":"bibr6-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/533590"},{"key":"bibr7-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091184.93122.09"},{"key":"bibr8-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/314712"},{"key":"bibr9-aph.1M085","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"bibr10-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"bibr11-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/421092"},{"key":"bibr12-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/423145"},{"key":"bibr13-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"bibr14-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-06"},{"key":"bibr15-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"bibr16-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"bibr17-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.05.007"},{"key":"bibr18-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3447-3450.2000"},{"key":"bibr19-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1062-1066.2000"},{"key":"bibr20-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.01.016"},{"key":"bibr21-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01538-07"},{"key":"bibr22-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01550.x"},{"key":"bibr23-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.595-597.2006"},{"key":"bibr24-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.655-656.2006"},{"key":"bibr25-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5384-5387.2005"},{"key":"bibr26-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl256"},{"key":"bibr27-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"bibr28-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00102-08"},{"key":"bibr29-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm170"},{"key":"bibr30-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01307-08"},{"key":"bibr31-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1318-1323.2003"},{"key":"bibr32-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"bibr33-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01854.x"},{"key":"bibr34-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2005.09.010"},{"key":"bibr35-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/600039"},{"key":"bibr36-aph.1M085","author":"Alam MM","year":"2007","journal-title":"Presented as a poster at the 45th Annual Meeting of the Infectious Diseases Society of America meeting"},{"key":"bibr37-aph.1M085","author":"Golik MV","year":"2008","journal-title":"Presented as a poster at the Inter-science Conference on Antimicrobial Agents and Chemotherapy\/Infectious Diseases Society of America"},{"key":"bibr38-aph.1M085","author":"Kullar R","year":"2009","journal-title":"Presented as a poster at: 19th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"bibr39-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.07.008"},{"key":"bibr40-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"bibr41-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.24.3207"},{"key":"bibr42-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.8.1223"},{"key":"bibr43-aph.1M085","doi-asserted-by":"publisher","DOI":"10.1086\/420818"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:41Z","timestamp":1777374401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":43,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1345\/aph.1M085"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m085","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}